Novavax’s COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company said Wednesday. The update sent Novavax’s stock up more than 21% in early trading. It also helped ease fears that the decision had been delayed by the Trump Administration, the Associated Press reported. Novavax makes the only… read on > read on >



















